Gordon J. Freeman

130.1k total citations · 51 hit papers
419 papers, 82.7k citations indexed

About

Gordon J. Freeman is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Gordon J. Freeman has authored 419 papers receiving a total of 82.7k indexed citations (citations by other indexed papers that have themselves been cited), including 301 papers in Immunology, 194 papers in Oncology and 60 papers in Molecular Biology. Recurrent topics in Gordon J. Freeman's work include Immune Cell Function and Interaction (195 papers), Cancer Immunotherapy and Biomarkers (141 papers) and T-cell and B-cell Immunology (132 papers). Gordon J. Freeman is often cited by papers focused on Immune Cell Function and Interaction (195 papers), Cancer Immunotherapy and Biomarkers (141 papers) and T-cell and B-cell Immunology (132 papers). Gordon J. Freeman collaborates with scholars based in United States, United Kingdom and China. Gordon J. Freeman's co-authors include Arlene H. Sharpe, Mary Keir, Manish J. Butte, Rafi Ahmed, E. John Wherry, Lee M. Nadler, Vijay K. Kuchroo, Kathleen M. Mahoney, Rebecca J. Greenwald and Baogong Zhu and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Gordon J. Freeman

414 papers receiving 81.6k citations

Hit Papers

PD-1 and Its Ligands in Tolerance and Immunity 1991 2026 2002 2014 2008 2018 2005 2014 2005 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. PD-1 and Its Ligands in Tolerance and Immunity
    2008 4.2k citations Gordon J. Freeman, Arlene H. Sharpe et al. profile →
  2. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
    2018 3.2k citations Xia Bu, Gordon J. Freeman et al. profile →
  3. Restoring function in exhausted CD8 T cells during chronic viral infection
    2005 3.1k citations Daniel L. Barber, E. John Wherry et al. Nature profile →
  4. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
    2014 2.7k citations Gordon J. Freeman, Scott J. Rodig et al. profile →
  5. THE B7 FAMILY REVISITED
    2005 1.9k citations Gordon J. Freeman, Arlene H. Sharpe et al. profile →
  6. CTLA-4 can function as a negative regulator of T cell activation
    1994 1.8k citations Gordon J. Freeman et al. profile →
  7. PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
    2009 1.7k citations Gordon J. Freeman, Vijay K. Kuchroo et al. The Journal of Experimental Medicine profile →
  8. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection
    2008 1.6k citations Gordon J. Freeman, E. John Wherry et al. profile →
  9. CD4+CD25high Regulatory Cells in Human Peripheral Blood
    2001 1.5k citations Gordon J. Freeman et al. profile →
  10. Programmed Death-1 Ligand 1 Interacts Specifically with the B7-1 Costimulatory Molecule to Inhibit T Cell Responses
    2007 1.4k citations Arlene H. Sharpe, Gordon J. Freeman et al. profile →
  11. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease
    2002 1.4k citations Tatyana Chernova, Edward Greenfield et al. Nature profile →
  12. The B7–CD28 superfamily
    2002 1.4k citations Arlene H. Sharpe, Gordon J. Freeman profile →
  13. Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy
    2016 1.3k citations Tahseen H. Nasti, Arlene H. Sharpe et al. Nature profile →
  14. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection
    2007 1.2k citations Arlene H. Sharpe, E. John Wherry et al. profile →
  15. Combination cancer immunotherapy and new immunomodulatory targets
    2015 1.0k citations Kathleen M. Mahoney, Gordon J. Freeman et al. profile →
  16. Tissue expression of PD-L1 mediates peripheral T cell tolerance
    2006 1.0k citations Spencer C. Liang, Yvette Latchman et al. The Journal of Experimental Medicine profile →
  17. PD-1 alters T-cell metabolic reprogramming by inhibiting glycolysis and promoting lipolysis and fatty acid oxidation
    2015 908 citations Gordon J. Freeman et al. profile →
  18. Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production
    2003 779 citations Edward Greenfield, Gordon J. Freeman et al. profile →
  19. Cloning of B7-2: a CTLA-4 Counter-Receptor That Costimulates Human T Cell Proliferation
    1993 773 citations Gordon J. Freeman et al. Science profile →
  20. Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
    2017 736 citations Xia Bu, Gordon J. Freeman et al. Nature profile →
  21. Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
    2017 724 citations Alice O. Kamphorst, Andreas Wieland et al. Science profile →
  22. Coinhibitory Pathways in Immunotherapy for Cancer
    2016 670 citations Gordon J. Freeman, Glenn Dranoff et al. profile →
  23. PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
    2013 657 citations Benjamin J. Chen, Bjoern Chapuy et al. Clinical Cancer Research profile →
  24. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
    2010 653 citations Koichi Araki, Gordon J. Freeman et al. Proceedings of the National Academy of Sciences profile →
  25. Antigen-specific regulatory T cells develop via the ICOS–ICOS-ligand pathway and inhibit allergen-induced airway hyperreactivity
    2002 633 citations Gordon J. Freeman, Edward Greenfield et al. profile →
  26. PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
    2017 612 citations Vikram R. Juneja, Kathleen A. McGuire et al. The Journal of Experimental Medicine profile →
  27. Enhancing SIV-specific immunity in vivo by PD-1 blockade
    2008 604 citations Baogong Zhu, Gordon J. Freeman et al. Nature profile →
  28. PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
    2016 555 citations Heather H. Sun, Gordon J. Freeman et al. profile →
  29. PD-1:PD-L inhibitory pathway affects both CD4+ and CD8+ T cells and is overcome by IL-2
    2002 548 citations Gordon J. Freeman et al. profile →
  30. Immunologic Purging of Marrow Assessed by PCR before Autologous Bone Marrow Transplantation for B-Cell Lymphoma
    1991 548 citations Gordon J. Freeman, Jerome Ritz et al. profile →
  31. Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance
    2003 538 citations Gordon J. Freeman, Vijay K. Kuchroo et al. profile →
  32. TIM-1 and TIM-4 Glycoproteins Bind Phosphatidylserine and Mediate Uptake of Apoptotic Cells
    2007 523 citations Baogong Zhu, Arlene H. Sharpe et al. profile →
  33. PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells
    2004 521 citations Yvette Latchman, Spencer C. Liang et al. Proceedings of the National Academy of Sciences profile →
  34. TIM genes: a family of cell surface phosphatidylserine receptors that regulate innate and adaptive immunity
    2010 520 citations Gordon J. Freeman et al. profile →
  35. Regulation of PD‐1, PD‐L1, and PD‐L2 expression during normal and autoimmune responses
    2003 518 citations Spencer C. Liang, Yvette Latchman et al. profile →
  36. B7-1 and B7-2 do not deliver identical costimulatory signals, since B7-2 but not B7-1 preferentially costimulates the initial production of IL-4
    1995 507 citations Gordon J. Freeman et al. profile →
  37. In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
    2017 504 citations Gordon J. Freeman et al. profile →
  38. Enhancing CD8+ T Cell Fatty Acid Catabolism within a Metabolically Challenging Tumor Microenvironment Increases the Efficacy of Melanoma Immunotherapy
    2017 481 citations Gordon J. Freeman et al. profile →
  39. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma
    2015 462 citations Kathleen M. Mahoney, Gordon J. Freeman et al. profile →
  40. LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade
    2018 462 citations Martin W. LaFleur, Eliezer M. Van Allen et al. profile →
  41. The importance of exosomal PDL1 in tumour immune evasion
    2020 457 citations Kathleen M. Mahoney, Gordon J. Freeman et al. profile →
  42. Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy
    2019 438 citations Gordon J. Freeman et al. profile →
  43. Coinhibitory Pathways in the B7-CD28 Ligand-Receptor Family
    2016 437 citations Sarah R. Klein, Gordon J. Freeman et al. profile →
  44. PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian Cancer
    2018 395 citations Gordon J. Freeman et al. profile →
  45. Proliferating Transitory T Cells with an Effector-like Transcriptional Signature Emerge from PD-1+ Stem-like CD8+ T Cells during Chronic Infection
    2019 377 citations Andreas Wieland, Bogumila T. Konieczny et al. profile →
  46. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity
    2017 373 citations Gordon J. Freeman et al. profile →
  47. Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
    2017 361 citations Scott J. Rodig, Peter S. Hammerman et al. profile →
  48. Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer
    2015 356 citations Nicolás A. Giraldo, Étienne Becht et al. Clinical Cancer Research profile →
  49. Tumor cells dictate anti-tumor immune responses by altering pyruvate utilization and succinate signaling in CD8+ T cells
    2022 196 citations Gordon J. Freeman, Arlene H. Sharpe et al. profile →
  50. Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance
    2023 120 citations Joon Seok Park, Francesca S. Gazzaniga et al. Nature profile →
  51. The B7:CD28 family and friends: Unraveling coinhibitory interactions
    2024 53 citations Apoorvi Chaudhri, Gordon J. Freeman et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Gordon J. Freeman United States 141 54.1k 38.6k 14.7k 8.3k 6.8k 419 82.7k
Drew M. Pardoll United States 132 46.7k 0.9× 45.0k 1.2× 23.5k 1.6× 8.8k 1.1× 5.7k 0.8× 403 83.2k
Mark J. Smyth Australia 143 52.9k 1.0× 37.6k 1.0× 20.2k 1.4× 5.1k 0.6× 5.5k 0.8× 595 81.6k
Arlene H. Sharpe United States 130 47.7k 0.9× 28.8k 0.7× 16.3k 1.1× 4.6k 0.6× 5.9k 0.9× 408 75.8k
Robert D. Schreiber United States 119 48.3k 0.9× 33.6k 0.9× 20.7k 1.4× 4.4k 0.5× 8.7k 1.3× 385 79.6k
Jedd D. Wolchok United States 119 29.7k 0.5× 45.3k 1.2× 16.2k 1.1× 11.0k 1.3× 3.3k 0.5× 568 65.0k
Lieping Chen United States 112 36.0k 0.7× 34.3k 0.9× 9.2k 0.6× 6.6k 0.8× 3.4k 0.5× 368 55.6k
Wolf H. Fridman France 100 31.2k 0.6× 27.6k 0.7× 16.6k 1.1× 8.5k 1.0× 2.6k 0.4× 529 57.4k
Hideo Yagita∥ Japan 128 43.5k 0.8× 21.7k 0.6× 18.2k 1.2× 3.3k 0.4× 5.2k 0.8× 912 67.3k
Paola Allavena Italy 93 33.3k 0.6× 22.0k 0.6× 14.6k 1.0× 4.9k 0.6× 4.1k 0.6× 295 56.8k
Vijay K. Kuchroo United States 133 59.0k 1.1× 20.6k 0.5× 13.2k 0.9× 2.7k 0.3× 5.2k 0.8× 426 79.1k

Countries citing papers authored by Gordon J. Freeman

Since Specialization
Citations

This map shows the geographic impact of Gordon J. Freeman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gordon J. Freeman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gordon J. Freeman more than expected).

Fields of papers citing papers by Gordon J. Freeman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gordon J. Freeman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gordon J. Freeman. The network helps show where Gordon J. Freeman may publish in the future.

Co-authorship network of co-authors of Gordon J. Freeman

This figure shows the co-authorship network connecting the top 25 collaborators of Gordon J. Freeman. A scholar is included among the top collaborators of Gordon J. Freeman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gordon J. Freeman. Gordon J. Freeman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Park, Joon Seok, Francesca S. Gazzaniga, Meng–Huang Wu, et al.. (2023). Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance. Nature. 617(7960). 377–385. 120 indexed citations breakdown →
2.
Bu, Xia, Vikram R. Juneja, Carol Reynolds, et al.. (2021). Monitoring PD-1 Phosphorylation to Evaluate PD-1 Signaling during Antitumor Immune Responses. Cancer Immunology Research. 9(12). 1465–1475. 11 indexed citations
3.
Derks, Sarah, Leonie K. de Klerk, Xiaoshu Xu, et al.. (2020). Characterizing diversity in the tumor-immune microenvironment of distinct subclasses of gastroesophageal adenocarcinomas. Annals of Oncology. 31(8). 1011–1020. 107 indexed citations
4.
Chaudhri, Apoorvi, et al.. (2018). PD-L1 Binds to B7-1 Only In Cis on the Same Cell Surface. Cancer Immunology Research. 6(8). 921–929. 136 indexed citations
5.
Kansy, Benjamin, Fernando Concha‐Benavente, Raghvendra M. Srivastava, et al.. (2017). PD-1 Status in CD8+ T Cells Associates with Survival and Anti-PD-1 Therapeutic Outcomes in Head and Neck Cancer. Cancer Research. 77(22). 6353–6364. 174 indexed citations
6.
Kamphorst, Alice O., Andreas Wieland, Tahseen H. Nasti, et al.. (2017). Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent. Science. 355(6332). 1423–1427. 724 indexed citations breakdown →
7.
Zhou, Jun, Kathleen M. Mahoney, Anita Giobbie‐Hurder, et al.. (2017). Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade. Cancer Immunology Research. 5(6). 480–492. 284 indexed citations
8.
Sridharan, Vishwajith, Evisa Gjini, Xiaoyun Liao, et al.. (2016). Immune Profiling of Adenoid Cystic Carcinoma: PD-L2 Expression and Associations with Tumor-Infiltrating Lymphocytes. Cancer Immunology Research. 4(8). 679–687. 77 indexed citations
9.
Callea, Marcella, Laurence Albigès, Mamta Gupta, et al.. (2015). Differential Expression of PD-L1 between Primary and Metastatic Sites in Clear-Cell Renal Cell Carcinoma. Cancer Immunology Research. 3(10). 1158–1164. 266 indexed citations
10.
Paterson, Alison M., Scott B. Lovitch, Peter T. Sage, et al.. (2015). Deletion of CTLA-4 on regulatory T cells during adulthood leads to resistance to autoimmunity. The Journal of Experimental Medicine. 212(10). 1603–1621. 172 indexed citations
11.
Giraldo, Nicolás A., Étienne Becht, Franck Pagès, et al.. (2015). Orchestration and Prognostic Significance of Immune Checkpoints in the Microenvironment of Primary and Metastatic Renal Cell Cancer. Clinical Cancer Research. 21(13). 3031–3040. 356 indexed citations breakdown →
12.
Mahoney, Kathleen M., Heather H. Sun, Xiaoyun Liao, et al.. (2015). PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells. Cancer Immunology Research. 3(12). 1308–1315. 103 indexed citations
13.
Reardon, David A., Prafulla C. Gokhale, Sarah R. Klein, et al.. (2015). Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunology Research. 4(2). 124–135. 302 indexed citations
14.
Concha‐Benavente, Fernando, Raghvendra M. Srivastava, Sumita Trivedi, et al.. (2015). Identification of the Cell-Intrinsic and -Extrinsic Pathways Downstream of EGFR and IFNγ That Induce PD-L1 Expression in Head and Neck Cancer. Cancer Research. 76(5). 1031–1043. 253 indexed citations
15.
Du, Ziming, Malak Abedalthagafi, Ayal A. Aizer, et al.. (2014). Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 6(7). 4704–4716. 126 indexed citations
16.
Chen, Benjamin J., Bjoern Chapuy, Jing Ouyang, et al.. (2013). PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies. Clinical Cancer Research. 19(13). 3462–3473. 657 indexed citations breakdown →
17.
Fuller, Michael J., Benoît Callendret, Baogong Zhu, et al.. (2013). Immunotherapy of chronic hepatitis C virus infection with antibodies against programmed cell death-1 (PD-1). Proceedings of the National Academy of Sciences. 110(37). 15001–15006. 140 indexed citations
18.
Lichterfeld, Mathias, Danlei Mou, Thai Cung, et al.. (2008). Telomerase activity of HIV-1–specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood. 112(9). 3679–3687. 59 indexed citations
19.
Radziewicz, Henry, Chris Ibegbu, Marina L. Fernandez, et al.. (2006). Liver-Infiltrating Lymphocytes in Chronic Human Hepatitis C Virus Infection Display an Exhausted Phenotype with High Levels of PD-1 and Low Levels of CD127 Expression. Journal of Virology. 81(6). 2545–2553. 387 indexed citations
20.
Latchman, Yvette, Spencer C. Liang, Yin Wu, et al.. (2004). PD-L1-deficient mice show that PD-L1 on T cells, antigen-presenting cells, and host tissues negatively regulates T cells. Proceedings of the National Academy of Sciences. 101(29). 10691–10696. 521 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Drew M. Pardoll Breakdown of academic impact, for papers by Mark J. Smyth Breakdown of academic impact, for papers by Arlene H. Sharpe Breakdown of academic impact, for papers by Robert D. Schreiber Breakdown of academic impact, for papers by Jedd D. Wolchok Breakdown of academic impact, for papers by Lieping Chen Breakdown of academic impact, for papers by Wolf H. Fridman Breakdown of academic impact, for papers by Hideo Yagita∥ Breakdown of academic impact, for papers by Paola Allavena Breakdown of academic impact, for papers by Vijay K. Kuchroo
Rankless by CCL
2026